Elshimi Esam, Morad Wesam, Elshaarawy Omar, Attia Ahmed
Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebine Elkom 32111, Egypt.
Department of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Shebine Elkom 32111, Egypt.
World J Gastrointest Endosc. 2020 Sep 16;12(9):285-296. doi: 10.4253/wjge.v12.i9.285.
Given most patients with distal malignant biliary obstruction present in the non-resectable stage, palliative endoscopic biliary drainage with fully covered metal stent (FCMS) or uncovered metal stent (UCMS) is the only available measure to improve patients' quality of life. Half covered metal stent (HCMS) has been recently introduced commercially. The adverse effects and stent function between FCMS and UCMS have been extensively discussed.
To study the duration of stent patency of HCMS and compare it with FCMS and UCMS to optimize biliary drainage in inoperable patients with distal malignant obstruction. Secondary aims in our study included evaluation of patients' survival and the rates of adverse events for each type of stent.
We studied 210 patients and randomized them into three equal groups; HCMS, FCMS and UCMS were inserted endoscopically.
Stent occlusion occurred in (18.6%, 17.1% and 15.7% in HCMS, FCMS and UCMS groups, respectively, = 0.9). Stent migration occurred only in patients with FCMS (8.6% of patients). Cholangitis and cholecystitis occurred in 11.4% and 5.7% of patients, respectively, in FCMS. Tumor growth occurred only in 10 cases among patients with UCMS after a median of 140 d, sludge occurred in nine, seven and one patients in HCMS, FCMS and UCMS, respectively ( = 0.04).
Given the prolonged stent functioning time, the use of HCMS is preferred over the use of UCMS and FCMS for optimizing biliary drainage in patients with distal malignant biliary obstruction.
鉴于大多数远端恶性胆管梗阻患者就诊时已处于不可切除阶段,采用全覆膜金属支架(FCMS)或裸金属支架(UCMS)进行姑息性内镜胆管引流是改善患者生活质量的唯一可用措施。半覆膜金属支架(HCMS)最近已投入商业使用。FCMS和UCMS之间的不良反应及支架功能已得到广泛讨论。
研究HCMS的支架通畅持续时间,并与FCMS和UCMS进行比较,以优化无法手术的远端恶性梗阻患者的胆管引流。本研究的次要目的包括评估患者的生存率以及每种支架的不良事件发生率。
我们研究了210例患者,并将他们随机分为三组,每组人数相等;通过内镜分别植入HCMS、FCMS和UCMS。
支架闭塞发生率分别为:HCMS组18.6%,FCMS组17.1%,UCMS组15.7%(P = 0.9)。仅FCMS组患者发生了支架移位(占患者的8.6%)。FCMS组分别有11.4%和5.7%的患者发生胆管炎和胆囊炎。UCMS组患者中仅10例在中位时间140天后出现肿瘤生长,HCMS组、FCMS组和UCMS组分别有9例、7例和1例患者出现胆泥(P = 0.04)。
鉴于HCMS的支架功能持续时间延长,对于优化远端恶性胆管梗阻患者的胆管引流,使用HCMS优于UCMS和FCMS。